.gif "IP Gear")
Bromocriptine is a sympatholytic D2-dopamine agonist that has been recently approved for the treatment of type 2 diabetes. This centrally acting antidiabetic agent has a novel mechanism of action and reduces plasma glucose, triglycerides, Free Fatty Acid (FFA) levels, and possibly cardiovascular events. The utility of bromocriptine in diabetes patients has been recognized, based on its activity in modulating central glucose and energy metabolism pathways.[3,4] A quick release formulation of bromocriptine, administered within two hours of awakening, is believed to augment low hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in a reduction in post meal plasma glucose levels, due to enhanced suppression of hepatic glucose production.
Whole article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152192/
Whole article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152192/
